C12N 2710/10332
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2710/10332 (Use of virus as therapeutic agent, other than vaccine) appears on 239 US grants and 453 published applications in this corpus.
Search patents in C12N- Granted patents
- 239
- Published applications
- 453
- Assignees
- 174
- Inventors
- 600
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 6 | 4 |
| 2002 | 4 | 11 |
| 2003 | 7 | 17 |
| 2004 | 7 | 12 |
| 2005 | 3 | 28 |
| 2006 | 8 | 20 |
| 2007 | 6 | 19 |
| 2008 | 8 | 19 |
| 2009 | 9 | 16 |
| 2010 | 5 | 16 |
| 2011 | 7 | 9 |
| 2012 | 5 | 11 |
| 2013 | 3 | 12 |
| 2014 | 4 | 7 |
| 2015 | 11 | 11 |
| 2016 | 5 | 18 |
| 2017 | 3 | 20 |
| 2018 | 12 | 23 |
| 2019 | 14 | 29 |
| 2020 | 17 | 23 |
| 2021 | 12 | 28 |
| 2022 | 16 | 33 |
| 2023 | 13 | 21 |
| 2024 | 13 | 23 |
| 2025 | 19 | 11 |
| 2026 | 10 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Engineered adenovirus vectors and uses thereof18 Aug 2026US 12,709,761 B2
- Oncolytic non-human adenoviruses and uses thereof30 Jun 2026US 12,668,612 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers16 Jun 2026US 12,653,851 B2Hangzhou Converd Co., Ltd.
- Oncolytic adenoviruses armed with heterologous genes16 Jun 2026US 12,653,852 B2Akamis Bio Limited
- Oncolytic non-human adenoviruses and uses thereof17 Sep 2026US 2026/0274898 A1Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Recombinant oncolytic adenovirus for cancer therapy20 Aug 2026US 2026/0240928 A1The Johns Hopkins University
- Fusion protein for localized activation of t-cells20 Aug 2026US 2026/0242470 A1Medizinische Hochschule Hannover
- Adenovirus armed with bispecific t cell engager20 Aug 2026US 2026/0242505 A1Akamis Bio Limited
- Dosing regime and formulations for type b adenoviruses30 Jul 2026US 2026/0216263 A1Akamis Bio Limited
Most cited
By later US patents
- Chimpanzee adenovirus vectors155US 6,083,716 AThe Trustees of the University of Pennsylvania · 2000
- Method for the production and purification of adenoviral vectors110US 6,194,191 B1Introgen Therapeutics, Inc. · 2001
- Methods and compositions comprising DNA damaging agents and p5399US 6,069,134 ABoard of Regents, The University of Texas System · 2000
- Cytopathic viruses for therapy and prophylaxis of neoplasia87US 5,846,945 AOnyx Pharmaceuticals, Inc. · 1998
- Method of reducing an immune response to a recombinant adenovirus81US 5,872,154 AThe Trustees of the University of Pennsylvania · 1999